This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK Expands Vaccine Collaboration With Zhifei in China
by Zacks Equity Research
GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034.
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
by Zacks Equity Research
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
by Zacks Equity Research
GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo
by Zacks Equity Research
The European Commission approves fully liquid presentation of GSK's meningococcal vaccine, Menveo, to protect against invasive meningococcal disease.
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
by Zacks Equity Research
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
by Zacks Equity Research
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
by Zacks Equity Research
The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
by Zacks Equity Research
INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
by Zacks Equity Research
GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.
GSK (GSK) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 9.48% and 2.16%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
by Zacks Equity Research
The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead, MRK Report Data From Investigational Combination Study for HIV
by Zacks Equity Research
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
by Zacks Equity Research
SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella.
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
by Zacks Equity Research
Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?
by Sundeep Ganoria
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
by Zacks Equity Research
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted population. A potential approval should boost GILD???s HIV portfolio.
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
by Zacks Equity Research
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.